Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Tg Therapeutics (TGTX) EBIT (2016 - 2025)

Historic EBIT for Tg Therapeutics (TGTX) over the last 10 years, with Q3 2025 value amounting to $29.4 million.

  • Tg Therapeutics' EBIT rose 13616.7% to $29.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $102.8 million, marking a year-over-year increase of 2045227.72%. This contributed to the annual value of $41.9 million for FY2024, which is 10321.33% up from last year.
  • Latest data reveals that Tg Therapeutics reported EBIT of $29.4 million as of Q3 2025, which was up 13616.7% from $34.8 million recorded in Q2 2025.
  • Tg Therapeutics' 5-year EBIT high stood at $114.8 million for Q3 2023, and its period low was -$92.9 million during Q4 2021.
  • For the 5-year period, Tg Therapeutics' EBIT averaged around -$22.5 million, with its median value being -$35.0 million (2022).
  • Its EBIT has fluctuated over the past 5 years, first skyrocketed by 42830.13% in 2023, then plummeted by 8916.75% in 2024.
  • Over the past 5 years, Tg Therapeutics' EBIT (Quarter) stood at -$92.9 million in 2021, then increased by 16.58% to -$77.5 million in 2022, then surged by 83.9% to -$12.5 million in 2023, then skyrocketed by 339.88% to $29.9 million in 2024, then decreased by 1.95% to $29.4 million in 2025.
  • Its EBIT was $29.4 million in Q3 2025, compared to $34.8 million in Q2 2025 and $8.6 million in Q1 2025.